MDxHealth (MDXH)

The company’s technology base includes proprietary DNA methylation biomarkers and related molecular platforms. These tools are intended to identify cancer-associated changes that may not be visible through standard clinical assessment alone. MDxHealth generates revenue mainly from clinical testing services, particularly in the United States, and also from licensing its biomarker intellectual property and technology platform to partners.

MDxHealth’s tests are positioned within the broader move toward precision medicine, where diagnostic information is used to tailor care to an individual patient’s risk profile. In urology, this can mean supporting decisions on whether to proceed with a biopsy, how to assess recurrence risk, or how to evaluate the likelihood that a patient may benefit from a specific course of care. The company serves physicians, healthcare systems, and payers that seek more actionable information than conventional measures can provide on their own.

Although incorporated in Belgium, MDxHealth has a significant commercial presence in the United States, which is its most important market, with additional activity in Europe. Its prospects depend on test adoption by urologists, reimbursement coverage, clinical validation, laboratory execution, and continued demand for molecular diagnostics in cancer care.